For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. | ...
Total product sales -- $7.3 billion in fiscal Q3 2025, up 4% sequentially from Q2 2025, with growth driven by the HIV ...
Investor's Business Daily on MSN
Gilead Sciences Dives As HIV Drug Misses Bullish Buy-Side Expectations
Gilead stock slumped late Thursday on soft product sales and lighter-than-expected revenue from its newcomer HIV prevention ...
People living with HIV who smoke are currently more likely to die from lung cancer than from HIV-related causes. Two cancer ...
More than 230 people became infected with HIV in Indiana, worsened by delayed action from former Gov. Mike Pence. Experts and ...
Wall Street expected sales of Yeztugo, which has an annual U.S. list price of about $28,000, at $37.5 million, according to ...
More than 40 years have passed since the CDC reported the first cases of HIV in the United States. In that time, we’ve ...
Researchers used cryo-EM to study how the HIV enzyme integrase arranges in 3D to slip its DNA into the host genome and pack ...
Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie recently updated its clinical study titled A ...
Shares in the company rose on Wednesday morning as a result, lifting to their highest level for more than a year.
GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit ...
NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), announced that Nanoviricides CEO Dr Anil ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback